ALLI (orlistat) by GSK is lipase inhibitors [moa]. First approved in 2007.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
ALLI (orlistat) is an oral intestinal lipase inhibitor approved in 2007 for weight management in adults. It works by blocking the absorption of dietary fats in the gastrointestinal tract, reducing caloric intake. The drug is indicated as an adjunct to a reduced-calorie diet and exercise program.
As LOE approaches, the commercial team is transitioning from growth maintenance to line extension or lifecycle management strategies, signaling consolidation of field and marketing resources.
Lipase Inhibitors
Intestinal Lipase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support
Effects of a Neurorehabilitation Program Based on CIMT and Non-invasive Neuromodulation Through C-tDCS on the Recovery of Paretic Upper Limb Function, Quality of Life, and Therapeutic Alliance in Women From the Araucanía Region Who Suffered a Stroke (CIMT + tDCS).
Worked on ALLI at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
GSK is hiring 10 roles related to this product
ALLI offers limited career growth opportunities as a maturing product approaching loss of exclusivity with minimal linked job postings. Roles on this brand focus on defensive commercial strategies, generic transition management, and maintaining physician/consumer loyalty during market erosion.